uploads/2018/09/Supernus.png

A Financial Overview of Supernus Pharmaceuticals in September

By

Updated

Revenue trends

In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.

In the second quarter, Supernus Pharmaceuticals generated revenues of $97.0 million from product sales and $1.8 million in royalty revenues. In the first half, Supernus Pharmaceuticals reported net product sales of $186.2 million compared to $129.7 million in the first half of 2017. Supernus Pharmaceuticals’ net product revenues are generated by the sales of Trokendi XR and Oxtellar XR.

Among Supernus Pharmaceuticals’ peers in the biopharmaceuticals market, Neurocrine Biosciences (NBIX) and Adamas Pharmaceuticals (ADMS) reported revenues of $96.91 million and $7.57 million, respectively, in the second quarter of 2017.

Article continues below advertisement

Expense trends

In the second quarter, Supernus Pharmaceuticals reported its cost of product sales, R&D (research and development) expenses, and SG&A (selling, general, and administrative) expenses of $3.7 million, $20.0 million, and $40.1 million, respectively. The company reported the cost of product sales, R&D expenses, and SG&A expenses of $3.9 million, $10.8 million, and $35.1 million, respectively, in the second quarter of 2017.

In the first half, Supernus Pharmaceuticals reported the cost of product sales, R&D expenses, and SG&A expenses of $7.0 million, $38.9 million, and $76.9 million, respectively, compared to $6.8 million, $20.4 million, and $63.31 million in the first half of 2017.

Earnings trends

In the second quarter, Supernus Pharmaceuticals reported net income and diluted EPS of $30.7 million and $0.57, respectively. It reported net income and diluted EPS of $17.4 million and $0.32, respectively, in the second quarter of 2017.

In the first half, Supernus Pharmaceuticals reported net income and diluted EPS of $57.1 million and $1.06, respectively, compared to $27.7 million and $0.52 in the first half of 2017.

Supernus Pharmaceuticals comprises ~0.29% of the iShares Core S&P Small-Cap ETF’s (IJR) total portfolio holdings.

Advertisement

More From Market Realist